Next Articles

Current Status and Prospects of Radiopharmaceuticals for Diagnosis

YOU Lin-yi1;GUO Zhi-de1,2;ZHANG Xian-zhong1   

  1. 1.Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China;2.Department of Isotope, China Institute of Atomic Energy, Beijing 102413, China
  • Published:2017-01-09



  1. 1.厦门大学公共卫生学院 分子影像暨转化医学研究中心,福建 厦门361102;2.中国原子能科学研究院 同位素研究所,北京102413


Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) technologies based on radiopharmaceuticals have become very effective diagnostic tools, which can reflect the functional and metabolic processes of living bodies at the molecular level. Radiopharmaceutical research and development provide a strong guarantee for molecular imaging and nuclear medicine development. Continuous research in radiopharmaceuticals by Chinese researchers have laid a solid foundation. This paper introduces the latest research progress in the field of radiopharmaceuticals for diagnosis in China in recent years, and prospects for the development of radiopharmaceuticals in China in the near future. The suggestions were proposed to strengthen the accelerator radionuclide development, radiopharmaceutical research, personnel training and other aspects of investment or research proposals in order to achieve this field to achieve more long-term development, better for human health services.

Key words: diagnosis, radiopharmaceuticals, precision medical


以放射性药物为基础的单光子断层扫描 (SPECT) 和正电子断层扫描 (PET) 已成为十分有效的诊断手段,可在分子水平反应活体功能和代谢过程。放射性药物的研发也为分子影像和核医学的发展提供了强有力的保障。国内放射性药物的研究已有坚实的基础,并且不断探索新的领域。本文介绍了近几年中国诊断用放射性药物领域的最新研究进展,对今后一段时期内中国放射性药物的发展进行了展望,并提出了加强加速器放射性核素开发、放射性药物研究等方面的建议,更好地为人类健康事业服务。

关键词: 诊断, 放射性药物, 精准医学